The company filed an amendment to its May 12, 2026, 8-K report. The correction addresses a typographical error where Michael S. Wyzga was inadvertently listed as a Class III director nominee instead of Murray W. Stewart, M.D. Stockholders approved the Second Amended and Restated 2017 Equity Incentive Plan, increasing available shares by 1,500,000. Stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent auditor for 2026. Stockholders approved the compensation of named executive officers on a non-binding advisory basis.